2021 Worldwide Chronic Obstructive Pulmonary Disease Industry Report - Featuring Afimmune, Allakos and Astellas Pharma Among Others - ResearchAndMarkets.com
Verona Pharma plc - American Depositary Shares (VRNA)
US:NASDAQ Investor Relations:
nasdaq.com/symbol/vrna/real-time
Company Research
Source: Business Wire
DUBLIN--(BUSINESS WIRE)--The "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Chronic obstructive pulmonary disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Report Highlights The companies and academics are working to assess challenges and seek opportunities that could influence Chronic obstructive pulmonary disease R&D. The therapies under development are focused on novel approaches to treat/improve Chronic obstructive pulmonary disease.Chronic obstructive pulmonary disease Emerging Drugs Chapters This segment of the Chronic obstructive pulmonary disease report
Show less
Read more
Impact Snapshot
Event Time:
VRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRNA alerts
High impacting Verona Pharma plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
VRNA
News
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
- Emphysema Treatment Market to Reach $8.7 Billion, Globally, by 2032 at 3.3% CAGR: Allied Market ResearchPR Newswire
- Verona Pharma plc (NASDAQ: VRNA) had its price target raised by analysts at Piper Sandler from $31.00 to $36.00. They now have an "overweight" rating on the stock.MarketBeat
- Verona Pharma plc (NASDAQ: VRNA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.MarketBeat
- Andrew Fisher Joins Verona Pharma as General Counsel [Yahoo! Finance]Yahoo! Finance
VRNA
Sec Filings
- 4/2/24 - Form 4
- 3/20/24 - Form ARS
- 3/20/24 - Form DEF
- VRNA's page on the SEC website